Gain Therapeutics (GANX) News Today $2.02 -0.20 (-9.01%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$2.26 +0.24 (+11.63%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Gain Therapeutics price target raised to $7 from $5 at Maxim2 hours ago | msn.comGain Therapeutics price target raised to $7 from $5 at Maxim2 hours ago | msn.comGain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim GroupOctober 7 at 12:36 PM | marketbeat.comGain Therapeutics Target of Unusually High Options Trading (NASDAQ:GANX)October 7 at 2:20 AM | americanbankingnews.comGain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement ...October 6 at 12:14 PM | markets.businessinsider.comStock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX)October 6 at 11:08 AM | marketbeat.comGain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s DiseaseOctober 6 at 8:31 AM | quiverquant.comQGain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®October 6 at 8:15 AM | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in SeptemberOctober 6 at 5:59 AM | marketbeat.comGain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.00 Average Price Target from BrokeragesSeptember 29, 2025 | americanbankingnews.comGain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Buy" from AnalystsSeptember 24, 2025 | marketbeat.comGain Therapeutics to Participate at Drug Discovery Innovation Programme 2025September 23, 2025 | globenewswire.comGain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s DiseaseSeptember 18, 2025 | markets.businessinsider.comGain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’sSeptember 18, 2025 | msn.comGain Therapeutics, Inc. Extends Phase 1b Study of GT-02287 for Parkinson's Disease TreatmentSeptember 18, 2025 | quiverquant.comQGain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's DiseaseSeptember 18, 2025 | globenewswire.comGain Therapeutics' (GANX) Buy Rating Reiterated at BTIG ResearchSeptember 10, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Gain Therapeutics (GANX), Terns Pharmaceuticals (TERN) and Novan (NOVN)September 6, 2025 | theglobeandmail.comGain Therapeutics receives Australian approval of Phase 1b dosing extensionSeptember 4, 2025 | msn.comGain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee RecommendationSeptember 4, 2025 | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 1, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of GANX Q3 EarningsAugust 29, 2025 | marketbeat.comGain Therapeutics Reports Q2 2025 Financial ResultsAugust 21, 2025 | tipranks.comRoth Capital Analysts Increase Earnings Estimates for GANXAugust 17, 2025 | marketbeat.comGain Therapeutics price target lowered to $6 from $7 at Roth CapitalAugust 13, 2025 | msn.comGain Therapeutics reports Q2 EPS (19c), consensus (17c)August 12, 2025 | msn.comGain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comGain Therapeutics (GANX) Projected to Post Earnings on ThursdayAugust 7, 2025 | marketbeat.comGain Therapeutics to Present at BTIG Annual Virtual Biotechnology ConferenceJuly 24, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX), Abbott Laboratories (ABT) and ANI Pharmaceuticals (ANIP)July 19, 2025 | theglobeandmail.comGain Therapeutics Announces Pricing of $7.0 Million Public OfferingJuly 16, 2025 | globenewswire.comGain Therapeutics stock falls after announcing public offeringJuly 16, 2025 | uk.investing.comGain Therapeutics Announces Proposed Public OfferingJuly 15, 2025 | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Buy" by AnalystsJuly 10, 2025 | marketbeat.comGain Therapeutics Inc News (GANX) - Investing.comJuly 8, 2025 | investing.comGain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 MutationJune 30, 2025 | globenewswire.comScotiabank Sticks to Its Buy Rating for Gain Therapeutics (GANX)June 27, 2025 | theglobeandmail.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Buy" by AnalystsJune 15, 2025 | marketbeat.comGain Therapeutics to Participate in Upcoming Investor ConferencesJune 10, 2025 | globenewswire.comGain Therapeutics Announces Oral Presentation at 2nd GBA1 MeetingMay 29, 2025 | globenewswire.comHC Wainwright Issues Optimistic Forecast for GANX EarningsMay 23, 2025 | marketbeat.comGotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX)May 23, 2025 | marketbeat.comGain Therapeutics (NASDAQ:GANX) Earns "Buy" Rating from HC WainwrightMay 21, 2025 | marketbeat.comRoth Capital Predicts Reduced Earnings for Gain TherapeuticsMay 20, 2025 | marketbeat.comGain Therapeutics (GANX) Gets a Buy from ScotiabankMay 16, 2025 | theglobeandmail.comGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate UpdateMay 14, 2025 | finanznachrichten.deGain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate UpdateMay 14, 2025 | globenewswire.comGain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related DisordersMay 13, 2025 | finance.yahoo.comGain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related DisordersMay 12, 2025 | globenewswire.comGain Therapeutics (GANX) to Release Earnings on TuesdayMay 8, 2025 | marketbeat.com Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GANX Media Mentions By Week GANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GANX News Sentiment▼0.860.55▲Average Medical News Sentiment GANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GANX Articles This Week▼92▲GANX Articles Average Week Get the Latest News and Ratings for GANX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Gain Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Neurogene News Tenaya Therapeutics News Tiziana Life Sciences News Aerovate Therapeutics News Voyager Therapeutics News Heron Therapeutics News Atea Pharmaceuticals News ProQR Therapeutics News Sagimet Biosciences News Black Diamond Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GANX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
